Evidence map›Paper›PMID 22392635›Full record

ArticleHepatology (Baltimore, Md.)2012

Inhibition of natural killer cells protects the liver against acute injury in the absence of glycine N-methyltransferase.

Laura Gomez-Santos, Zigmund Luka, Conrad Wagner, Sara Fernandez-Alvarez, Shelly C Lu, Jose M Mato, Maria L Martinez-Chantar, Naiara Beraza

Open access · bronzeAbstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 62 citations in OpenAlex.

  1. Molecular mechanisms in MASLD/MASH-related HCC.Hepatology (Baltimore, Md.) · 2025
    Review
  2. Article
  3. Review
  4. Article
  5. TNFα and IFNγ cooperate for efficient pro- to anti-inflammatory transition of macrophages during muscle regeneration.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  6. Review
  7. Article
  8. Review
  9. Digoxin mitigates diethylnitrosamine-induced acute liver injury in mice via limiting production of inflammatory mediators.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022
    Article
  10. Review
  11. The Role of Natural Killer Cells in Nonalcoholic Steatohepatitis: An Ongoing Debate.Cellular and molecular gastroenterology and hepatology · 2022
    Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Bile Acid Toxicity and Protein Kinases.Advances in experimental medicine and biology · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Laura Gomez-SantosDepartment of Metabolomics, CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberedh), Technology Park of Bizkaia, 48160-Derio, Bizkaia, Spain.
Zigmund Luka
Conrad Wagner
Sara Fernandez-Alvarez
Shelly C Lu
Jose M Mato
Maria L Martinez-Chantar
Naiara Beraza
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESCIC bioGUNE · ESUniversity of Southern California · USVanderbilt University · USVA Tennessee Valley Healthcare System · US

Funding

Role of SAMe in Pathogenesis and Treatment of Non-Alcholic Fatty Liver DiseaseR01AT001576 · NCCIH · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LU, SHELLY CHI-LOO · 2002 to 2018
$5.0M
NCCIH NIH HHS AT-1576NCCIH NIH HHS R01 AT001576
6 · The paper itself

Abstract

unlabelledGlycine N-methyltransferase (GNMT) catabolizes S-adenosylmethionine (SAMe), the main methyl donor of the body. Patients with cirrhosis show attenuated GNMT expression, which is absent in hepatocellular carcinoma (HCC) samples. GNMT(-/-) mice develop spontaneous steatosis that progresses to steatohepatitis, cirrhosis, and HCC. The liver is highly enriched with innate immune cells and plays a key role in the body's host defense and in the regulation of inflammation. Chronic inflammation is the major hallmark of nonalcoholic steatohepatitis (NASH) progression. The aim of our study was to uncover the molecular mechanisms leading to liver chronic inflammation in the absence of GNMT, focusing on the implication of natural killer (NK) / natural killer T (NKT) cells. We found increased expression of T helper (Th)1- over Th2-related cytokines, tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-R2/DR5, and several ligands of NK cells in GNMT(-/-) livers. Interestingly, NK cells from GNMT(-/-) mice were spontaneously activated, expressed more TRAIL, and had strong cytotoxic activity, suggesting their contribution to the proinflammatory environment in the liver. Accordingly, NK cells mediated hypersensitivity to concanavalin A (ConA)-mediated hepatitis in GNMT(-/-) mice. Moreover, GNMT(-/-) mice were hypersensitive to endotoxin-mediated liver injury. NK cell depletion and adoptive transfer of TRAIL(-/-) liver-NK cells protected the liver against lipopolysaccharide (LPS) liver damage.

conclusionOur data allow us to conclude that TRAIL-producing NK cells actively contribute to promote a proinflammatory environment at early stages of fatty liver disease, suggesting that this cell compartment may contribute to the progression of NASH.

Indexed as

Acute DiseaseAdoptive TransferAnimalsApoptosisChemical and Drug Induced Liver InjuryConcanavalin ADisease Models, AnimalFatty LiverGlycine N-MethyltransferaseKiller Cells, NaturalLipopolysaccharidesLymphocyte DepletionMaleMiceMice, KnockoutMitogensConcanavalin AGlycine N-MethyltransferaseGnmt protein, mouseLipopolysaccharidesMitogensTNF-Related Apoptosis-Inducing LigandTnfsf10 protein, mouse

Identifiers

PMID22392635
PMCPMC3378767
OpenAlexW2027233915

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.